Clinical Trials in Ireland — Country Dashboard | 456 EU Studies

Filter these 456 trials by condition, phase, sponsor and more.

Open in Search →

456 Registered trials

178 Recruiting

249 Completed trials

203 Sponsors active

69 Research sites

Phase III

Phase II

Phase III: 290 Phase II/III: 30 Phase II: 81 Phase I/II: 10 Phase III/IV: 5 Phase IV: 13 Phase I: 12 Phase I (Other): 2 Phase I (FiH): 12 Other: 1

Oversight events in trials active here:

35 serious breaches 170 temporary halts 9 urgent safety measures 11 unexpected events 26 corrective measures across 73 trials

View oversight register →

Top conditions

Non-small cell lung cancer 18 Amyotrophic lateral sclerosis 8 Ovarian cancer 7 Non-small cell lung cancer metastatic 7 Crohn's disease 6 Idiopathic pulmonary fibrosis 5 Non-small cell lung cancer stage III 5 Fallopian tube cancer 5 Ovarian epithelial cancer 5 Hormone receptor positive HER2 negative breast cancer 4 Hepatocellular carcinoma 4 Non-small cell lung cancer stage II 4

Top sponsors

Merck Sharp & Dohme LLC 57 AbbVie Deutschland GmbH & Co. KG 16 Bristol-Myers Squibb Services Unlimited Company 15 AstraZeneca AB 11 Cancer Trials Ireland 11 University College Dublin 11 Novartis Pharma AG 8 Takeda Development Center Americas Inc. 8 Celgene Corp. 7 Novo Nordisk A/S 7 Regeneron Pharmaceuticals Inc. 7 Boehringer Ingelheim Espana S.A. 6

Cities with most trials

All 20 cities →

All trials

456 total

Clinical trial of MK-7648A in adults and children with skin cancer Not authorised

2022-501417-31-00 Phase III High-risk Resected Melanoma Merck Sharp & Dohme LLC
HARMONi-3 Not authorised

2023-504989-37-00 Phase III Metastatic Squamous Non-small Cell Lung Cancer Summit Therapeutics Sub Inc.
A study to investigate efficacy and safety with pegtibatinase compared to placebo in participants ≥12 to ≤65 years of age with classical hom… Pending

2023-504135-40-00 Phase III Classical Homocystinuria Travere Therapeutics Inc.
A prospective, open-label, randomized, multicenter phase-III trial to evaluate the efficacy of pirtobrutinib and epcoritamab compared with R… Pending

2024-513445-37-00 Phase III previously untreated RT, irrespective of risk factors and di… University Of Cologne
Extension Study of ACT-EARLY Pending

2024-513676-18-00 Phase III Transthyretin Amyloidosis Eidos Therapeutics Inc.
POSITRON - PsilOcybin with pSychologIcal supporT foR cOcaiNe: a randomised controlled pilot feasibility trial of psilocybin with psychologic… Pending

2024-515147-32-02 Phase II Cocaine addiction Trinity College Dublin
Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND) Pending

2024-516805-22-00 Phase III Major Depressive Disorder Cybin IRL Limited
A Phase 1 Study of TORL-1-23 in Advanced Cancer Pending

2024-517189-40-00 Phase I Advanced Cancer Torl Biotherapeutics LLC
A Study to Learn about the Long-Term Health of Adult Participants from a Previous Study of a New Melanoma Treatment Pending

2024-517729-20-00 Phase II Melanoma Regeneron Pharmaceuticals Inc.
An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH). Pending

2024-520218-23-00 Phase II/III Pulmonary Arterial Hypertension Inhibikase Therapeutics Inc.
ACUMEN: Acute High Dose Melatonin for Encephalopathy of the Newborn Pending

2025-520538-49-00 Phase I Moderate-Severe Hypoxic-Ischaemic Encephalopathy (HIE) University College London
OCEAN(a)-PreEvent - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction to Prevent first major cardiovascular Events Pending

2025-520554-11-00 Phase III Cardiovascular Disease Amgen Inc.
Selective decontamination of the digestive tract in preventing surgical site infections in elective colorectal surgery: a randomised control… Pending

2025-520725-20-00 Phase II Surgical site infection University Hospital Limerick
Safety and efficacy of T10430 eye drops in controlling paediatric myopia progression Pending

2025-521563-13-01 Phase II Paediatric myopia Laboratoires Thea
A Study to Evaluate the Long-term Safety and Tolerability of Admilparant in Participants with Pulmonary Fibrosis. Pending

2025-522373-10-00 Phase III Progressive pulmonary fibrosis and Idiopathic pulmonary fibr… Bristol-Myers Squibb Services Unlimited Company
Usnoflast Neuromuscular Investigation for Treatment Efficacy in ALS (UNITE-ALS) Pending

2025-522580-15-00 Phase II Amyotrophic Lateral Sclerosis (ALS) Zydus Therapeutics Inc.
Phase 3 Study of INCB123667 Versus Investigator's Choice of Chemotherapy in Platinum Resistant Ovarian Cancer With Cyclin E1 Overexpression Pending

2025-522748-42-00 Phase III Ovarian cancer Incyte Corp.
Safety and Efficacy of VX-828/Deutivacaftor Combination Therapy With and Without Tezacaftor in Subjects With Cystic Fibrosis Pending

2025-523400-72-00 Phase II Cystic fibrosis Vertex Pharmaceuticals Inc.
A Phase 1/2, Open‑Label, Multi‑Center, Dose Escalation, Dose Expansion, and Single Repeat Dose Study of TSRA‑196 in Adults With the PiZZ Gen… Pending

2025-523497-16-00 Phase I (FiH) Lung and/or Liver Disease Associated with Alpha-1 Antitrypsi… Tessera Therapeutics Inc.
A Phase 1 Study of AIR-001 in Adults with AATD. Pending

2025-523558-14-00 Phase I Alpha-1 Antitrypsin Deficiency Airna Corp.
A Phase 1/2, Multicenter, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, a… Pending

2025-523590-42-00 Phase I (FiH) Locally Advanced or Metastatic Solid Tumors Crescent Biopharma Inc.
Efficacy and safety of vamifeport in adult subjects with HFE-related hereditary hemochromatosis Pending

2025-523793-16-00 Phase II Homeostatic iron regulator gene-related hereditary hemochrom… CSL Behring LLC
A clinical trial studying the effect of Tirzepatide in women living with endometrial cancer Pending

2025-523877-40-00 Phase II Endometrial adenocarcinoma University College Dublin
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents with Severe Uncontrolled Asthma (SOLAIRIA-1) Pending

2025-524040-35-00 Phase III Severe uncontrolled asthma Generate Biomedicines Inc.

Showing 1–24 of 456 trials

← All countries